{"concreteType":"org.sagebionetworks.repo.model.table.QueryResultBundle","queryResult":{"concreteType":"org.sagebionetworks.repo.model.table.QueryResult","queryResults":{"headers":[{"columnType":"STRING","name":"projectName","id":"70035"},{"columnType":"ENTITYID","name":"id","id":"2510"},{"columnType":"STRING","name":"fundingAgency","id":"34789"},{"columnType":"STRING","name":"citation","id":"70036"},{"columnType":"STRING","name":"doi","id":"70037"},{"columnType":"STRING","name":"tumorType","id":"34799"},{"columnType":"STRING","name":"diseaseFocus","id":"62354"}],"concreteType":"org.sagebionetworks.repo.model.table.RowSet","tableId":"syn16857542","etag":"e11e814c-9572-4b2d-a0cb-c236fd1ccd4f","rows":[{"values":["Synodos NF2","syn2343195","CTF","Angus SP, et al. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol (2018).","10.1093/neuonc/noy046","schwannoma, meningioma","Neurofibromatosis 2"],"versionNumber":0,"rowId":0},{"values":["Synodos NF2","syn2343195","CTF","The Synodos for NF2 Consortium, et al. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One (2018).","10.1371/journal.pone.0197350","schwannoma, meningioma","Neurofibromatosis 2"],"versionNumber":0,"rowId":1},{"values":["Child NF1 Quality of Life Measures","syn4939878","NTAP","Nutakki K et al. Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods. J Neurooncol (2017)","10.1007/s11060-016-2351-2;10.1111/jspn.12174","Plexiform Neurofibroma","Neurofibromatosis 1"],"versionNumber":0,"rowId":2},{"values":["Child NF1 Quality of Life Measures","syn4939878","NTAP","Draucker CB et al. The health-related quality of life of children, adolescents, and young adults with neurofibromatosis type 1 and their families: Analysis of narratives. J Spec Pediatr Nurs (2017).","10.1007/s11060-016-2351-2;10.1111/jspn.12174","Plexiform Neurofibroma","Neurofibromatosis 1"],"versionNumber":0,"rowId":3},{"values":["Drug Screening of pNF Cell Lines","syn4939906","NTAP","Ferrer M, et al. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Nature Sci Data (2018).","10.1038/sdata.2018.106","Plexiform Neurofibroma","Neurofibromatosis 1"],"versionNumber":0,"rowId":4},{"values":["NF1 Dermal Neurofibroma Longitudinal Natural History Study and Selumetinib Clinical Trial","syn8012530","NTAP","Cannon A, et al. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet J Rare Dis (2018).","10.1186/s13023-018-0772-z","Cutaneous Neurofibroma","Neurofibromatosis 1"],"versionNumber":0,"rowId":5},{"values":["Cutaneous Neurofibroma Data Resource","syn4984604","CTF","Gosline SJC, et al. A high-throughput molecular data resource for cutaneous neurofibromas. Sci Data (2017).","10.1038/sdata.2017.45","Cutaneous Neurofibroma","Neurofibromatosis 1"],"versionNumber":0,"rowId":6},{"values":["Cutaneous Neurofibroma Data Resource","syn4984604","CTF","Allaway RJ, et al. Cutaneous neurofibromas in the genomics era: current understanding and open questions. Br J Cancer (2018).","10.1038/s41416-018-0073-2","Cutaneous Neurofibroma","Neurofibromatosis 1"],"versionNumber":0,"rowId":7},{"values":["Synodos NF1 Preclinical Models (Iowa Sanford Exemplar)","syn5610418","CTF","White KA, et al. A porcine model of neurofibromatosis type 1 that mimics the human disease. JCI Insight (2018).","10.1172/jci.insight.120402","Plexiform Neurofibroma","Neurofibromatosis 1"],"versionNumber":0,"rowId":8},{"values":["Synodos NF1 Preclinical Models (Iowa Sanford Exemplar)","syn5610418","CTF","Meyerholtz DK, et al. Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. J Histochem Cytochem (2017).","10.1369/0022155417729357","Plexiform Neurofibroma","Neurofibromatosis 1"],"versionNumber":0,"rowId":9},{"values":["Synodos NF1 Low Grade Glioma","syn5698493","CTF","Ricker CA, et al. Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma. Front Oncol (2016).","10.3389/fonc.2016.00259","Low Grade Glioma","Neurofibromatosis 1"],"versionNumber":0,"rowId":10},{"values":["Plexiform Neurofibroma Model Systems for Preclinical Drug Screening","syn7217928","NTAP","Brock EJ, Ji K, Reiners JJ Jr. & Mattingly RR. How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization. Mini Rev Med Chem. 2016 ; 16(5): 358-369.","10.2174/1389557515666151001154002","Plexiform Neurofibroma","Neurofibromatosis 1"],"versionNumber":0,"rowId":11},{"values":["pNF Cell Line Characterization Studies","syn4939874","NTAP","Ferrer M, et al. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Nature Sci Data (2018).","10.1038/sdata.2018.106","Plexiform Neurofibroma","Neurofibromatosis 1"],"versionNumber":0,"rowId":12},{"values":["Drug-Target Explorer","syn11672851","CTF","Allaway RJ, et al. Probing the chemical-biological relationship space with the Drug Target Explorer. J Chem Inf (2018).","10.1186/s13321-018-0297-4",null,"Multiple"],"versionNumber":0,"rowId":13},{"values":["NF Cell Line Compound Screens","syn11817821","CTF","Guo J, et al. Comprehensive pharmacological profiling of neurofibromatosis cell lines. Am J Cancer Res (2017).","doi:10.7303/syn16857059.1","MPNST","Neurofibromatosis 1"],"versionNumber":0,"rowId":14}]}},"selectColumns":[{"columnType":"STRING","name":"projectName","id":"70035"},{"columnType":"ENTITYID","name":"id","id":"2510"},{"columnType":"STRING","name":"fundingAgency","id":"34789"},{"columnType":"STRING","name":"citation","id":"70036"},{"columnType":"STRING","name":"doi","id":"70037"},{"columnType":"STRING","name":"tumorType","id":"34799"},{"columnType":"STRING","name":"diseaseFocus","id":"62354"}],"columnModels":[{"columnType":"STRING","name":"projectName","maximumSize":89,"id":"70035"},{"columnType":"ENTITYID","name":"id","id":"2510"},{"columnType":"STRING","name":"fundingAgency","maximumSize":4,"id":"34789"},{"columnType":"STRING","name":"citation","maximumSize":198,"id":"70036"},{"columnType":"STRING","name":"doi","maximumSize":44,"id":"70037"},{"columnType":"STRING","name":"tumorType","maximumSize":22,"id":"34799"},{"columnType":"STRING","name":"diseaseFocus","maximumSize":19,"id":"62354"}],"facets":[]}